Participants 60 91 3
anti-herpes virus therapy in MS
Participants 204 253 5
patients with relapsing-remitting MS in a phase 2
Participants 443 558 7
Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment
Participants 560 633 6
Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5
Participants 1892 1991 3
patients with relapsing-remitting MS who had two or more relapses during the previous 2-year period
